MX2010013484A - Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. - Google Patents
Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.Info
- Publication number
- MX2010013484A MX2010013484A MX2010013484A MX2010013484A MX2010013484A MX 2010013484 A MX2010013484 A MX 2010013484A MX 2010013484 A MX2010013484 A MX 2010013484A MX 2010013484 A MX2010013484 A MX 2010013484A MX 2010013484 A MX2010013484 A MX 2010013484A
- Authority
- MX
- Mexico
- Prior art keywords
- ketorolac
- pharmaceutical formulation
- intranasal administration
- compositions
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta invención concierne a composiciones terapéuticas, particularmente a composiciones acuosas nebulizables, y a formulaciones en dosis unitaria que comprenden ketorolaco o a una sal aceptable farmacéuticamente, solos o en combinación con lidocaina o con una sal de ésta aceptable farmacéuticamente. Las composiciones son administradas nasalmente a un sujeto en necesidad de éstas para tratar dolor o inflamación.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6152208P | 2008-06-13 | 2008-06-13 | |
US16025409P | 2009-03-13 | 2009-03-13 | |
PCT/US2009/047095 WO2009152369A1 (en) | 2008-06-13 | 2009-06-11 | Pharmaceutical formulation of ketorolac for intranasal administration |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010013484A true MX2010013484A (es) | 2011-03-29 |
Family
ID=40910889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010013484A MX2010013484A (es) | 2008-06-13 | 2009-06-11 | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. |
Country Status (10)
Country | Link |
---|---|
US (3) | US20100016402A1 (es) |
EP (1) | EP2296625A1 (es) |
JP (1) | JP2011524366A (es) |
KR (1) | KR20110017433A (es) |
CN (1) | CN102137656A (es) |
AU (1) | AU2009257385A1 (es) |
CA (1) | CA2727094A1 (es) |
MX (1) | MX2010013484A (es) |
TW (1) | TW201002368A (es) |
WO (1) | WO2009152369A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551454B2 (en) * | 2009-03-13 | 2013-10-08 | Luitpold Pharmaceuticals, Inc. | Device for intranasal administration |
WO2012127497A1 (en) | 2011-03-04 | 2012-09-27 | Cadila Healthcare Limited | Stable pharmaceutical compositions of ketorolac or salts thereof |
MX2021007213A (es) * | 2018-12-19 | 2021-09-23 | Grace therapeutics Inc | Composicion terapeutica de lidocaina intranasal. |
EP4110329A4 (en) * | 2020-02-24 | 2024-04-10 | Yinuoke Medicine Science Tech Company Ltd | COMPOSITIONS AND METHODS FOR TREATING CYTOKINE STORM AND CYTOKINE RELEASE SYNDROME |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4089969A (en) * | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
US4778810A (en) * | 1987-01-08 | 1988-10-18 | Nastech Pharmaceutical Co., Inc. | Nasal delivery of caffeine |
US4943587A (en) * | 1988-05-19 | 1990-07-24 | Warner-Lambert Company | Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition |
US4885287A (en) * | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
IT1250691B (it) * | 1991-07-22 | 1995-04-21 | Giancarlo Santus | Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac. |
US6090368A (en) * | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
US20020006961A1 (en) * | 1999-05-14 | 2002-01-17 | Katz Stanley E. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
DE10118306A1 (de) * | 2001-04-12 | 2002-10-17 | Bayer Ag | Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation |
ZA200704869B (en) * | 2004-12-23 | 2009-02-25 | Roxro Pharma Inc | Therapeutic compositions for intranasal administration of ketorolac |
JP4367559B2 (ja) * | 2007-08-10 | 2009-11-18 | トヨタ自動車株式会社 | 車両 |
-
2009
- 2009-06-11 AU AU2009257385A patent/AU2009257385A1/en not_active Abandoned
- 2009-06-11 MX MX2010013484A patent/MX2010013484A/es not_active Application Discontinuation
- 2009-06-11 JP JP2011513702A patent/JP2011524366A/ja active Pending
- 2009-06-11 KR KR1020117000568A patent/KR20110017433A/ko not_active Application Discontinuation
- 2009-06-11 EP EP09763657A patent/EP2296625A1/en not_active Withdrawn
- 2009-06-11 CA CA2727094A patent/CA2727094A1/en not_active Abandoned
- 2009-06-11 CN CN2009801220684A patent/CN102137656A/zh active Pending
- 2009-06-11 WO PCT/US2009/047095 patent/WO2009152369A1/en active Application Filing
- 2009-06-11 TW TW098119561A patent/TW201002368A/zh unknown
- 2009-06-12 US US12/483,586 patent/US20100016402A1/en not_active Abandoned
-
2012
- 2012-09-04 US US13/603,232 patent/US20120329849A1/en not_active Abandoned
-
2015
- 2015-11-20 US US14/947,319 patent/US20160136089A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20110017433A (ko) | 2011-02-21 |
US20100016402A1 (en) | 2010-01-21 |
JP2011524366A (ja) | 2011-09-01 |
WO2009152369A1 (en) | 2009-12-17 |
US20160136089A1 (en) | 2016-05-19 |
TW201002368A (en) | 2010-01-16 |
EP2296625A1 (en) | 2011-03-23 |
CA2727094A1 (en) | 2009-12-17 |
AU2009257385A1 (en) | 2009-12-17 |
CN102137656A (zh) | 2011-07-27 |
US20120329849A1 (en) | 2012-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
MX2007007504A (es) | Composiciones terapeuticas para la administracion intranasal de ketorolaco. | |
WO2013090278A3 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
IL242268A0 (en) | Combinations and forms of administration of therapeutic factors and combined treatment | |
WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
IN2014DN03093A (es) | ||
MY161078A (en) | Topical formulation for a jak inhibitor | |
MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
MX2019003467A (es) | Formulaciones y metodos para la administracion vaginal de antiprogestinas. | |
MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
UA105644C2 (uk) | Способи лікування легеневих порушень складами ліпосомального амікацину | |
MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
HK1176318A1 (en) | Injection device | |
TN2011000651A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application | |
UA103791C2 (uk) | Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу | |
WO2011074015A3 (en) | Composition of pharmaceutical product to treat sexual dysfunction | |
MX2009011900A (es) | Curacion de herida diabetica. | |
DE602008006700D1 (es) | ||
MX2010013484A (es) | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. | |
WO2009088673A3 (en) | Pharmaceutical composition | |
MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |